
Xeris Biopharma Holdings, Inc.
XERSHealthcare|Biotechnology|US
$15.20
+2.12 (+16.21%)
Cash / Share
$0.72
Next Earnings Report
Mar 1, 2027
EPS est. $0.03 · Revenue est. $111.0M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.
Upcoming Data Readouts (0)
No upcoming completion dates found in active trials.
Recent Press Releases
Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
Nov 5, 2026 · Business Wire
Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors
Nov 2, 2026 · Business Wire
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
Oct 22, 2026 · Business Wire
Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
Oct 15, 2026 · Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 2, 2026 · Business Wire
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
Sep 9, 2026 · Business Wire
Xeris Announces Details for XP-8121 Program Overview Webinar
Aug 26, 2026 · Business Wire
SEC Filings (45)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 5, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Nov 5, 2026 | 8-K | Material event | DocumentIndex |
| Nov 2, 2026 | 8-K | Material event | DocumentIndex |
| Oct 30, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Oct 14, 2026 | 8-K | Material event | DocumentIndex |
| Sep 9, 2026 | 8-K | Material event | DocumentIndex |
| Aug 6, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Aug 6, 2026 | 8-K | Material event | DocumentIndex |
| Jul 31, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Jul 17, 2026 | 8-K | Material event | DocumentIndex |
| Jun 30, 2026 | 8-K | Material event | DocumentIndex |
| Jun 11, 2026 | 8-K | Material event | DocumentIndex |
| Jun 5, 2026 | 8-K | Material event | DocumentIndex |
| May 7, 2026 | 10-Q | Quarterly report | DocumentIndex |
| May 7, 2026 | 8-K | Material event | DocumentIndex |
| Apr 23, 2026 | ARS | Annual report to holders | DocumentIndex |
| Apr 23, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 23, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Apr 21, 2026 | 8-K | Material event | DocumentIndex |
| Mar 27, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 2, 2026 | S-8 | Employee stock plan | DocumentIndex |
| Mar 2, 2026 | 10-K | Annual report | DocumentIndex |
| Mar 2, 2026 | 8-K | Material event | DocumentIndex |
| Jan 30, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jan 8, 2026 | 8-K | Material event | DocumentIndex |
| Dec 1, 2025 | 8-K | Material event | DocumentIndex |
| Nov 6, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Nov 6, 2025 | 8-K | Material event | DocumentIndex |
| Aug 7, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Aug 7, 2025 | 8-K | Material event | DocumentIndex |
| Jun 4, 2025 | 8-K | Material event | DocumentIndex |
| Jun 3, 2025 | 8-K | Material event | DocumentIndex |
| May 13, 2025 | EFFECT | DocumentIndex | |
| May 8, 2025 | 10-Q | Quarterly report | DocumentIndex |
| May 8, 2025 | 8-K | Material event | DocumentIndex |
| Apr 23, 2025 | ARS | Annual report to holders | DocumentIndex |
| Apr 23, 2025 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 23, 2025 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Mar 28, 2025 | 8-K | Material event | DocumentIndex |
| Mar 6, 2025 | S-8 | Employee stock plan | DocumentIndex |